Spyratos F, Hacene K, Tubiana-Hulin M, Pallud C, Brunet M
Département de Biologie, Centre René Huguenin, St-Cloud, France.
Eur J Cancer Clin Oncol. 1989 Aug;25(8):1233-40. doi: 10.1016/0277-5379(89)90420-3.
Nine prognostic variables were evaluated for their significance in predicting the overall survival (OS), the length of disease-free survival (DFS) and the length of metastasis-free survival (MFS) of 1262 patients with primary breast cancer. The variables studied were: UICC clinical stage; menopausal status; histologic grade; number of involved nodes; anatomic tumor size; estrogen and progesterone receptors; local and adjuvant therapies. Three sequential multivariate analyses, at 2, 5 and 10 years, using the Cox proportional hazard regression model, were carried out to identify those variables most highly related to the criteria studied (overall, disease-free, metastasis-free survivals) and especially to fully evaluate the effects of hormonal receptors on prognosis and their stability over time. Our results showed that number of involved nodes and histologic grade were the most significant prognostic factors for all periods of time and whatever the criterion studied; ER had no predictive value while PR was an independent prognostic factor for metastasis-free survival at 2 years (P = 0.01) and 5 years (P = 0.02) but lost its significance at 10 years (P = 0.06). In the subgroup of 261 patients who received prolonged post-operative adjuvant chemotherapies, PR was the main prognostic factor for MFS at 2 years (P = 0.03) and the second at 5 years (P = 0.05) just after number of involved nodes. In the 1001 patients who did not receive prolonged post-operative adjuvant chemotherapies ER was significant for MFS at 5 and 10 years. The present data urge the need for a periodic redefinition of prognostic factors in primary breast cancer.
对9个预后变量在预测1262例原发性乳腺癌患者的总生存期(OS)、无病生存期(DFS)和无转移生存期(MFS)方面的意义进行了评估。研究的变量包括:国际抗癌联盟(UICC)临床分期;绝经状态;组织学分级;受累淋巴结数量;肿瘤解剖学大小;雌激素和孕激素受体;局部及辅助治疗。采用Cox比例风险回归模型,在2年、5年和10年进行了三项连续的多变量分析,以确定与所研究标准(总生存期、无病生存期、无转移生存期)最密切相关的变量,特别是全面评估激素受体对预后的影响及其随时间的稳定性。我们的结果表明,无论所研究的标准如何,受累淋巴结数量和组织学分级在所有时间段都是最显著的预后因素;雌激素受体(ER)无预测价值,而孕激素受体(PR)在2年(P = 0.01)和5年(P = 0.02)时是无转移生存期的独立预后因素,但在10年时失去其显著性(P = 0.06)。在接受延长术后辅助化疗的261例患者亚组中,PR是2年时无转移生存期的主要预后因素(P = 0.03),在5年时仅次于受累淋巴结数量,为第二主要预后因素(P = 0.05)。在未接受延长术后辅助化疗的1001例患者中,雌激素受体在5年和10年时对无转移生存期有显著意义。目前的数据表明,有必要对原发性乳腺癌的预后因素进行定期重新定义。